english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Risdiplam (Evrysdi°) in spinal muscular atrophy. Continue the evaluation

FEATURED REVIEW Risdiplam has been authorised in the European Union for use in patients aged 2 months or older with spinal muscular atrophy. How do Prescrire's editors rate this drug in this situation?
Full review (3 pages) available for download by subscribers.
1 November 2022

A change of paradigm

 Editorial  It is time to extricate ourselves from the paradigm in which drugs are the mainstay of our response to health problems, and to embrace one in which they are just one option rather than an automatic reflex.
1 November 2022

Liraglutide (Saxenda°) in obesity in adolescents: not acceptable

Liraglutide is authorised for use in patients with type 2 diabetes and in obese adults. Its marketing authorisation has now been extended to include obese adolescents.
1 November 2022

Cannabidiol (Epidyolex°) in epilepsy associated with tuberous sclerosis complex

Cannabidiol, a substance present in cannabis, has antiepileptic properties. Having already been authorised in the European Union for children with certain severe forms of epilepsy, it has now also been authorised for use in patients aged 2 years and older who have epileptic seizures associated with tuberous sclerosis complex.
1 November 2022

Messenger RNA covid-19 vaccines: an update on adverse effects

 COVID-19  Two messenger RNA (mRNA) covid-19 vaccines, tozinameran (Comirnaty° from the pharmaceutical companies Pfizer and BioNTech) and elasomeran (Spikevax° from Moderna), have been marketed in the European Union since late 2020. What is known, as of mid-2022, about the adverse effects of these mRNA covid-19 vaccines?
1 November 2022

Etifoxine: a dangerous drug still on the market

The European reassessment of etifoxine, a dangerous drug with no demonstrated efficacy, has only led to some modifications of the summary of product characteristics (SmPC) and the package leaflet.
1 November 2022

  The 2022 Prescrire Prize is awarded in Paris
  to 6 healthcare-related books or projects

The recipients of the 2022 "Prix Prescrire" awards were announced in Paris on 6 October 2022, by the editors of the independent medical journal La Revue Prescrire. The prize recognises books, other works or initiatives of particular interest to the general public and/or healthcare professionals.
06 October 2022

Viral vector covid-19 vaccines authorised in the European Union: a review of their adverse effects

FEATURED REVIEW The first-choice options for the prevention of covid-19 are the messenger RNA (mRNA) covid-19 vaccines, with the two viral vector vaccines, covid-19 vaccine ChAdOx1-S (Vaxzevria° from AstraZeneca) and covid-19 vaccine Ad26.COV2-S (Jcovden° from Janssen-Cilag), as second choices. What adverse effects are known to occur with these viral vector vaccines?
Full review (3 pages) available for download by subscribers.
1 October 2022

In the October issue of Prescrire International: Trastuzumab deruxtecan (Enhertu°) in HER2-positive metastatic breast cancer

FREE DOWNLOAD Evaluation of trastuzumab deruxtecan (Enhertu°), authorised for treatment of some inoperable or metastatic breast cancers, was mainly based on one non-comparative trial, with a primary endpoint that is not necessarily objective.
Full text available for free download.
1 October 2022

An African covid-19 vaccine, despite foot-dragging by drug companies

 Editorial  As part of a WHO technology-transfer initiative, the South African biotech company Afrigen succeeded in producing a small quantity of a copy of Moderna's covid-19 vaccine elasomeran (Spikevax°). Since then, Afrigen has been working on the development and large-scale production of formulations that would be cheaper and less heat-sensitive than the original vaccine, to facilitate its use in Africa.
1 October 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90